Clinical trials: Locally Advanced Pancreatic Carcinoma
Locally Advanced Pancreatic Cancer
A Study of Locally Advanced Pancreatic Cancer
The primary end point is to evaluate the time to progression after gemcitabine alone versus Gemcitabine-based combination induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.
- Trial name
- NCT01063192
- Testing
- Gemcitabine, Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)
- Volunteers
- 73 people
- Sponsor
- National Health Research Institutes, Taiwan
Locally Advanced Pancreatic Cancer
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.
- Trial name
- NCT05653453
- Testing
- Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel, Gemcitabine hydrochloride and albumin binding paclitaxel
- Where
- 5 sites in China
- Volunteers
- 512 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Pancreatic Cancer
A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer
Pancreatic cancer progresses rapidly and has a higher death rate. Albumin-bound paclitaxel is a new generation of paclitaxel . Albumin-bound paclitaxel is recommended as a class 1A evidence treating patients with pancreatic…
- Trial name
- NCT03768687
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreas, Cancer
Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
Patients with unresectable pancreatic cancer in most of cases cannot benefit from percutaneous ablation modalities, due to high risk of procedure-related complications.
- Conditions
- Pancreas, Cancer, Locally Advanced Pancreatic Cancer, Non-invasive Treatment
- Trial name
- NCT01786850
- Testing
- Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)
- Where
- Italy
- Sponsor
- University of Roma La Sapienza
Advanced Malignant Solid Neoplasm, ALK Positive
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of ceritinib and combination chemotherapy in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Advanced Malignant Solid Neoplasm, ALK Positive, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
- Trial name
- NCT02227940
- Testing
- Ceritinib, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Neoplasms, Biliary Tract Neoplasms
The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer
The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.
- Trial name
- NCT00268840
- Testing
- Docetaxel, Gemcitabine
- Where
- France
- Volunteers
- 45 people
- Sponsor
- ARCAGY/ GINECO GROUP
Pancreatic Cancer, Unresectable Pancreatic Cancer
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of stereotactic radiation therapy given in five fractions (30 Gray in 5 fractions) followed by gemcitabine in patients with locally advanced pancreatic cancer.
- Trial name
- NCT01304160
- Testing
- stereotactic body radiotherapy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Pancreatic Cancer
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
This Phase Ib dose escalation study will evaluate BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1, and Imprime PGG, a glucan contained in yeast that is essential in triggering a…
- Trial name
- PM-01 (NCT02132403)
- Testing
- BTH1704, IMPRIME PGG, Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago
Pancreatic Cancer
A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new experimental drug, demcizumab (OMP-21M18), when given in combination with gemcitabine with or without (+/-) Abraxane®.
- Trial name
- NCT01189929
- Testing
- Demcizumab, Abraxane®, Gemcitabine
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 57 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Pancreas Cancer
Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
- Trial name
- LAPC (NCT05191940)
- Testing
- Particle-therapy using protons or carbon ions, Blood sampling, Magnetic resonance imaging
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- EBG MedAustron GmbH
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
- Trial name
- PREDICT (NCT03468335)
- Testing
- Irinotecan Liposomal Injection [Onivyde]
- Where
- 35 sites in Germany
- Volunteers
- 151 people
- Sponsor
- AIO-Studien-gGmbH
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
CREO - Microwave Ablation Feasibility Study
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer.
- Conditions
- Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III
- Trial name
- NCT07817147
- Testing
- EUS-Guided MWA Device
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Banner Health
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Cancer
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally…
- Trial name
- NCT06346808
- Testing
- Oncolytic virus Plus Anti-PD1 and Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Pancreatic Cancer
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.
- Trial name
- NCT01781520
- Testing
- DC-CIK Treatment, S1, Best supportive care
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Capital Medical University
Adenocarcinoma
Next Generation Sequencing of Tumor Cells in Locally Advanced Pancreatic Adenocarcinoma
All patients referring to the U.O .of Digestive Endoscopy of the Humanitas Hospital to undergo EUS with biopsy in the pre-treatment evaluation of locally advanced pancreatic adenocarcinoma, satisfying all the inclusion criteria…
- Trial name
- LAPC-NGS-A/001 (NCT03578939)
- Testing
- Biopsy EUS guided
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Istituto Clinico Humanitas
Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
To evaluate the clinical efficacy (objective response rate, ORR) of mass spectrometry-based absolute quantification-guided selection and matching of ADC/PDC therapy in patients with locally advanced or metastatic pancreatic…
- Trial name
- PROBE (NCT07825753)
- Testing
- Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Fudan University
Pancreatic Cancer
A Phase II Study of Locally Advanced Pancreatic Cancer
The primary end point is to evaluate the 9-month progression free survival rate and safety profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic…
- Trial name
- NCT01867892
- Testing
- ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT, ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
- Volunteers
- 86 people
- Sponsor
- National Health Research Institutes, Taiwan
Locally Advanced and Metastatic Pancreatic Cancer
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.
- Trial name
- NCT00910741
- Testing
- Nanoplatin (NC-6004) and Gemcitabine
- Where
- 5 sites in Singapore, Taiwan
- Volunteers
- 40 people
- Sponsor
- NanoCarrier Co., Ltd.